Wire Stories
-
311Gold Resource Corporation Announces Q3 2023 Conference Call
DENVER–(BUSINESS WIRE)–Gold Resource Corporation (NYSE American: GORO) (the “Company”) will host a conference call Friday, November 3, 2023 at 10:00 a.m. Eastern...
-
446Polaris and OrionVM Partner to Next-Gen Cloud Transform Queensland ICT Market
OrionVM’s MicroPoP Technology Enables Leading Australian Data Centre to Uniquely Underpin Cloud Workloads, Including Enterprise Cloud, AI and Storage Solutions SYDNEY &...
-
360New Chinese Restrictions on Supply of Natural Graphite Will Negatively Impact Batteries Used in EV Market
Westwater Resources Offers Domestic Alternatives CENTENNIAL, Colo.–(BUSINESS WIRE)–Westwater Resources, Inc. (NYSE: American: WWR), an energy technology and battery-grade natural graphite company (“Westwater...
-
419Nanban Ventures Sends Letter Highlighting Steps Being Taken to Protect Investors
DALLAS–(BUSINESS WIRE)–Nanban Ventures LLC (“Nanban Ventures”), a Dallas-based venture capital firm investing in startups and other private companies that are committed to...
-
462Avistone Announces Phase II Results for Vebreltinib, a c-Met Tyrosine Kinase Inhibitor (TKI) at the European Society for Clinical Oncology (ESMO) Congress
BEIJING–(BUSINESS WIRE)–Avistone Biotechnology Co., Ltd. (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, announced preliminary results of...
-
515ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Daiichi Sankyo and AstraZeneca’s ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the...
-
581Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37%...
-
686Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median PFS benefit,...
-
373athenahealth’s Annual ‘September is for Service’ Program Supports 50 Nonprofit Organizations Worldwide
Month-long campaign delivers more than $100,000 to nonprofit partners, with record employee participation BOSTON–(BUSINESS WIRE)–athenahealth, Inc., a leading provider of network-enabled software...
-
389Edgecore Networks Introduces its New Wi-Fi 6 & Wi-Fi 6E Access Points for Mastering Every Terrain
Embracing Resilient Wi-Fi 6 & Wi-Fi 6E Connectivity with Edgecore Wi-Fi HSINCHU, Taiwan–(BUSINESS WIRE)–Edgecore Networks, a leading provider of traditional and open...
